Agree.
Jon and the CEO of DXB (Nikki) used to work together at Acrux Limited - an Australian drug pharmaceutical company that has successfully developed and commercialised multiple products globally.
Both NEU and DXB have less than 15 full time staff.
DXB is currently running a large Phase 3 Trial across 170+ sites globally.
Jon and Nikki often present at the same investor events.
So I am confident Jon is able to seek global Phase 3 Trial information from Nikki.
And likewise, I am confident Nikki is able to obtain information regarding the negotiation of global licensing deals from Jon / NEU.
It will now come down to the Phase 3 trial design and feedback from the FDA.
I am confident that Jon and NEU know what they are doing to maximise vale for NEU and its shareholders.
GLTAHs
The Whens and Whys of Top Biotech M&A Deals, page-71
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.13 |
Change
-0.010(0.07%) |
Mkt cap ! $1.933B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $15.30 | $14.96 | $6.401M | 422.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.16 | 6015 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |